Sales in Q4 came in lower than expected, but the EBITDA was in line with our estimate. The discrepancy between our forecast and the actual outcome stemmed from lower-than-expected sales related to warm perfusion (including durable goods). While the company failed to live up to our high-set expectations, we see that the growth trend is pointing in the right direction and that clinical programs are about progress to the next phase.